US2009286841A1PendingUtilityA1

Certain chemical entities, compositions, and methods

66
Assignee: SMITHKLINE BEECHAM CORPPriority: May 6, 2004Filed: Mar 2, 2009Published: Nov 19, 2009
Est. expiryMay 6, 2024(expired)· nominal 20-yr term from priority
Inventors:Xiangping QianAndrew McdonaldHan-Jle ZhouLuke W. AshcraftBing YaoHong JiangJennifer Kuo Chen HuangJlanchao WangDavid J. Morgans, Jr.Bradley P. MorganGustave BergnesDashyant DhanakSteven David KnightNicholas D. AdamsCynthia A. ParrishKevin DuffyDuke M. FitchRosanna Tedesco
C07C 275/40C07C 259/18C07D 235/16C07F 9/6561C07C 255/59C07C 255/60C07D 261/08C07F 9/6506C07D 403/12C07D 271/10C07D 235/06C07D 271/06C07D 235/18C07C 235/48C07C 307/10C07D 207/273C07D 413/06C07D 263/32C07D 498/04C07D 213/30A61P 37/00C07D 233/64C07C 257/18C07C 271/28C07D 211/76C07D 277/56C07C 235/52C07C 257/08C07C 255/57C07C 235/50C07D 285/125C07D 233/70C07D 235/26C07D 285/02A61P 31/10C07D 271/07C07C 271/24C07D 471/04C07D 233/61C07C 275/26C07C 311/37C07C 2601/02C07D 231/14C07D 263/10C07D 257/04C07D 277/42C07C 311/46C07D 403/10C07D 263/12A61P 35/00C07D 295/145C07D 333/38C07D 211/34C07D 239/36C07D 271/113A61P 9/00C07D 277/30C07D 231/12C07D 295/155C07C 2601/14C07C 271/20C07C 281/06C07C 275/42C07C 237/22C07D 249/08
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled) 
   
   
       47 . A compound that is [4-((1R)-2,2,2-trifluoro-isopropoxy)-3-chlorophenyl]-N-[(1S)-3-hydroxy-1-({4-[2-(1-hydroxy-isopropyl)-1-methylimidazol-4-yl]phenyl}methyl)propyl]carboxamide. 
   
   
       48 . A composition comprising at least one pharmaceutical excipient and a compound according to  claim 47 . 
   
   
       49 . The composition of  claim 48  wherein the composition is formulated for administration by a route chosen from oral, subcutaneous, intravenous, intranasal, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, and intraocular. 
   
   
       50 . The composition of  claim 49  wherein the composition is formulated for oral administration. 
   
   
       51 . The composition of  claim 50  wherein the composition is formulated as a tablet, capsule, or liquid. 
   
   
       52 . The composition of  claim 50  wherein the at least one pharmaceutical excipient is selected from diluents, binders, glidants, lubricants, disintegrants, colors, flavors, sweetening agents, polymers, waxes and other solubility-retarding materials. 
   
   
       53 . The composition of  claim 49  wherein the composition is formulated for intravenous administration. 
   
   
       54 . The composition of  claim 53  wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes. 
   
   
       55 . The composition of  claim 53  wherein the at least one pharmaceutical excipient is water for injection USP. 
   
   
       56 . The composition of  claim 48  wherein the composition is formulated for parenteral administration. 
   
   
       57 . The composition of  claim 56  wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes. 
   
   
       58 . The composition of  claim 56  wherein the at least one pharmaceutical excipient is water for injection USP.

Join the waitlist — get patent alerts

Track US2009286841A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.